You're watching...
FBN's Adam Shapiro on Eli-Lilly's Alzheimer's drug failure and how it’s impacting investors.
Also in this playlist...
Auto-advance: ON
Auto-advance
This transcript is automatically generated
Thank you so much -- and shares of Eli Lilly up on reports of some success in late it's late stage trials of Lilly's experimental alzheimer's drug Adam Shapiro has more on this developing story and -- -- are actually not.
While they were not a success the tests actually I did not do what Eli Lilly was hoping they would do but what they discovered and it looked at the data.
Was promised him in -- region quote from the CEO of Eli -- who said.
That the original studies did not meet their primary end points but we were encouraged by the -- data which appears to show here's the key and why investors are excited.
A slowing of cognitive decline in alzheimer's patients it goes on to say we intend to discuss these data with -- regulatory authorities.
To gain their insights on potential next steps you know other drug makers are pursuing some kind of pharmaceutical that would help people who have alzheimer's but they have -- -- given up on that.
Eli -- seems to have found something at least for the first time will slow the cognitive.
Decline in alzheimer's patients now.
But we talk about how many.
Should be shown to have some kind of positive benefit their five point two million people.
We had alzheimer's in the US today.
By 2045 we'll be six point seven million by 2050.
Between eleven million to sixteen million.
So Eli Lilly it's a setback but it's a set back with a silver lining their approaching regulators to see.
If -- go forward -- the kinds of tests because again first drug to show that it does slow.
Cognitive decline.
Thank you Adam good to see if it's again out of -- -- we were together most of the morning thank you again.
